Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab

Fig. 2

Percentage LDH changes relative to baseline. Legend: Percent change in LDH [%] of each patient in three categorized groups - the solid line for patients receiving 24 cycles of durvalumab, the dotted line for patients receiving at least 12 cycles of durvalumab, and the broken line for patients receiving less than 12 cycles of durvalumab

Back to article page